pSivida Corp. , a leading developer of small size, extended-release drug delivery technologies, with two of the three sustained-release ophthalmic delivery FDA approved for the treatment of the back of the eye diseases, announced that its CEO, Dr. Paul Ashton, will discuss drug delivery eye during a presentation at the annual conference of diabetes six London, Friday, Jan.It should also address the two-day conference of representatives of GlaxoSmithKline, Sanofi-Aventis, Merck Sharp & Dohme, F. Hoffman-La Roche, AstraZeneca, Eli Lilly, Astellas, Pharmacuegticals Regeneron, and Fovea Pharmaceuticals and ophthalmologists Medpace leader at the University of Oxford and Moorfields Eye Hospital.
In his presentation, Mr. It is planned to discuss new technologies for the distribution of drugs, including those in developing pSivida, which can help to get drugs directly in the eye area where they can be more effective in treating the underlying disease. As part of this presentation, Dr. Ashton is also intended to summarize recent preliminary results of phase 3 FAME macular Iluvien in patients with diabetes who were reported last month by pSivida and its licensee, Alimera Sciences.
Rash and diarrhea were reported more frequently in the Tarceva group compared to placebo.
- Metformin (Brand name: Glucophage). Important safety information and side effects
- Simvastatin. Medical Uses
Few patients leave the study of side effects.